Reversal of Signs and Symptoms of a B-Cell Lymphoma in a Patient Using Only Low-Dose Naltrexone

Primary tabs

field_vote: 
Average: 10 (1 vote)
Publication type: 
Therapeutic intervention: 
Therapeutic Substance(s): 
Number of included patients: 

Cited from the article:
DiscussionThis case report describes the treatment of a 61-yearoldman with biopsy-proven FL. His initial physicalexamination and PET/CT scan showed multiplelarge, metabolically active, pathologic lymph nodesthat impressively demonstrated complete resolutionwithin 6 months of commencing therapy with nocturnallyadministered LDN. This case not only suggeststhe potential role of LDN in the treatment ofFLs but also highlights the ease of maintaining compliancewith this therapeutic regimen. In addition,T.M. was prescribed a healthy diet, a nutritional supplementregimen, and intravenous ALA. He did notremain compliant with any of these 3 modalities.Thus, in this case study, we are choosing to attributeT.M.’s impressive achievement of clinical and radiologicalremission to the LDN alone.At the time of this report, and per telephonecommunication from the patient’s wife, T.M.remains asymptomatic from his disease, now 1 yearafter his last CT/PET imaging. T.M. remained onLDN for 6 months only; he stopped taking it inJune 2006. Perhaps these results represent a periodof spontaneous remission in the potential waxingand waning course of his follicular lymphoma.However, given the rapidity of the nodal waxing, itsequally rapid dimensional wane and the summarilylow cost of the medication, its ease of administration,and possibility for efficacy, LDN deserves furtherinvestigation.We believe that by the mechanisms presentedherein, LDN demonstrates significant potential toincrease disease-free as well as overall survival in peoplewith FL. It is hoped that biomedical science will soondevelop cures for the currently incurable cancers,perhaps via gene therapy, cancer vaccines, or otherbiological platforms. Until that time, we need to considertreatments that have the potential to alter the course ofcancers for the better. Especially needed are treatmentssuch as LDN that are inexpensive, demonstrate ease ofcompliance, and are bereft of the side effects plaguingmost currently used conventional therapies.